BioVex begins trials for genital herpes vaccine

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges

Funding drugs for rare diseases

MHT's Julie Donnelly: Life science startups finding investments

OncoPep licenses cancer vaccine, moves to add $500K to Series A [February 13, 2012]

VBI Vaccines pulls in $2.2M debt round [February 13, 2012]

Zalicus, Hydra team up on pain treatment [February 10, 2012]

Ironwood stock offering aims for $80M [February 10, 2012]

BioVex Inc., a Woburn-based developer of cancer and infectious disease drugs and vaccines, has begun its Phase 1 clinical trial of its genital herpes vaccine, ImmunoVAXHSV2.

The trial, led by Simon Barton and located in the U.K. at the Chelsea and Westminster Hospital, uses healthy patients in an ascended dose trial to measure the safety and immune response of the live attenuated vaccine candidate.

If the vaccine shows promise from the Phase 1 study, BiOVex founder and chief technology officer Robert Coffin said the company would move the vaccine candidate into later stage efficiency trials.

ImmunoVEXHSV2 is made to express 76 of about 80 proteins found in HSV-2, the causative agent of genital herpes.

BioVex announced at the beginning of the year that it had named Tim Hanke as its vice president of commercial operations, responsible for moving the company’s “oncolytic vaccine” OncoVEX GM-CSF product to commercialization.

BioVex has its headquarters in Woburn and maintains its research and development facility in Oxford, England.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.